After 2 years of confusion and anxiety from conflicting research results, physicians have new guidance in determining which patients with cardiovascular disease who take antiplatelet therapy will reap the most benefit from also taking a proton pump inhibitor (PPI) to reduce the risk of gastrointestinal (GI) bleeding.
In mid-November, the American College of Cardiology Foundation, the American College of Gastroenterology, and the American Heart Association released a consensus document that gives a green light to the concomitant use of antiplatelet drugs and PPIs in patients who are at high risk for upper GI bleeding (http://tinyurl.com/289g85d).
Voelker R. Experts OK Antiplatelets and PPIs for Heart Patients With GI Bleeding Risks. JAMA. 2011;305(2):135–136. doi:10.1001/jama.2010.1907
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.